Polaryx Therapeutics (PLYX) Common Equity (2024 - 2026)

Polaryx Therapeutics (PLYX) has reported Common Equity for 3 consecutive years, with $10.9 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Common Equity rose 237.0% year-over-year to $10.9 million in Q2 2026; TTM through Jun 2026 was $10.9 million, a 237.0% increase from a year earlier, with the FY2025 full-year figure at $4.6 million, down 3.12% from the prior year.
• Common Equity was $10.9 million for Q2 2026 at Polaryx Therapeutics, up from $2.5 million in the prior quarter.
• Over five years, Common Equity peaked at $10.9 million in Q2 2026 and troughed at $2.5 million in Q1 2026.
• A 3-year average of $5.0 million and a median of $4.4 million in 2025 frame the typical range for Common Equity.
• The widest YoY moves for Common Equity: up 237.0% in 2026, down 41.51% in 2026.
• Over 3 years, Common Equity stood at $4.7 million in 2024, then slipped by 3.12% to $4.6 million in 2025, then jumped by 139.63% to $10.9 million in 2026.
• The last three Common Equity figures came in at $10.9 million (Q2 2026), $2.5 million (Q1 2026), and $4.6 million (Q4 2025), per Business Quant data.